| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel And Secretary
1 company
Kasinger James R. serves as a General Counsel And Secretary at CRSP. Across recent SEC filings that breaks down to 0 buys and 22 sells. Those positions are worth an estimated $4.7M at current prices.
Historically, Kasinger James R.'s trades have earned a middling insider score of 60/100 across 13 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of +3.0%.
The biggest single holding is CRSP (~$4.7M) as General Counsel And Secretary. The recent filings there lean toward selling, a net 79,192 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | CRSP Crispr Therapeutics AG | General Counsel And Secretary | Sale+OE | 11,542 | $53.67 | $619,492.35 | -13.4% | -26.0% | +3.1% | |
| Oct 14, 2024 | CRSP Crispr Therapeutics AG | General Counsel And Secretary | Sale+OE | 1,089 | $46.28 | $50,398.92 | -1.7% | -18.8% | +45.1% | |
| Mar 12, 2024 | CRSP Crispr Therapeutics AG | General Counsel And Secretary | Sale+OE | 3,947 | $77.15 | $304,514.50 | -6.1% | -20.3% | -42.2% | |
| Feb 20, 2024 | CRSP Crispr Therapeutics AG | General Counsel And Secretary | Sale+OE | 1,913 | $79.67 | $152,408.71 | -3.2% | -29.5% | -32.7% | |
| Jan 19, 2021 | CRSP Crispr Therapeutics AG | General Counsel And Secretary | Sale+OE | 27,500 | $204.94 | $5,635,943.70 | -55.1% | - | - |